According to a new comprehensive report from The Insight Partners, the global colorectal cancer treatment market is observing significant growth owing ...

Alvotech and Advanz Pharma announce positive EMA opinion for AVT06, a biosimilar to Eylea®, advancing access for eye disorder treatments in Europe.

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach ...

Alvotech, Kashiv, and Advanz Pharma report positive results for their biosimilar AVT23 compared to Xolair in clinical study.

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) ...

Positive results from the confirmatory clinical efficacy and safety study of ADL-018, proposed biosimilar to XOLAIR® The clinical study met its primary endpoint in Chronic Spontaneous Urticaria ...

Kashiv BioSciences has reported encouraging topline outcomes from the randomised confirmatory trial of the proposed biosimilar to Novartis’ Xolair (omalizumab), ADL-018.

Biosimilar Resource Center Visit our Biosimilar Resource Center. A primer for U.S. physicians on the role of biosimilars in medical treatment.

Fresenius Kabi continues the expansion of its biosimilars portfolio in the U.S. with the introduction of Conexxence (denosumab-bnht) and Bomyntra® (denosumab-bnht) in the United States.